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Received 13 October 2009; received in revised form 15 January 2010; accepted 15 January 2010Abstract The term “environmental epigenetic modifications” refers to alterations in phenotype triggered by environmental
stimuli via epigenetic mechanisms. Epidemiologic and animal model studies show that a subset of such environmental
epigenetic marks may affect susceptibility to chronic diseases. A growing body of evidence regarding incompleteness of
reprogramming indicates that the potential retention of pathogenic environmental epigenetics in human induced pluripotent
stem cells (iPSCs) should be seriously considered. Given this possibility, the optimization of methods for the generation of
human induc pluripotent stem cells may require the identification of epigenetically appropriate somatic cell sources. Similarly,
techniques for controlling epigenetic modification by environmental factors may also play a critical role in the development of
epigenetically stable sources of pluripotent stem cells.
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doi:10.1016/j.scr.2010.01.001of the outputs of scientific investigations and their applica-
tions in technology include predictability, reproducibility,
and controllability, and, importantly, findings are expected
to be generalizable in the sense that when two systems are
uniform and constant, the causes of events in one system can
serve as the basis for predictions in its counterpart. The
human body, however, is exceedingly complex and diverse,
which frustrates the direct use of predictions from models in.
158 K. Sakuradamedical care. The genetic sequences of any two individuals
will show several millions of single nucleotide substitutions,
and the human phenotype also changes as a result of
epigenetic mechanisms. It is thus understandable that
predicting and controlling such a complex, diverse, dynamic,
and irreversible organism as the human body represents a
tremendous scientific challenge. In clinical studies, popula-
tion-based statistics are used to make inferences about
heterogeneous patient groups, and the uniformity of compo-
nents of therapeutic entities in the face of this inter-
individual diversity remains a major challenge in cell-based
medicine.
The advent and advances in the study of human induced
pluripotent stem cells (iPSCs) have raised considerable public
interest, particularly with respect to their potential applica-
tions in stem-cell-based therapy and in vitro cellularmodels of
disease (Takahashi et al., 2007; Yu et al., 2007; Park et al.,
2008; Masaki et al., 2008; Lowry et al., 2008; Park et al., 2008;
Dimos et al., 2008; Ebert et al., 2009; Soldner et al., 2009;
Raya et al., 2009). This enthusiasm is partially rooted in the
assumption that human iPSCs are equivalent to human
embryonic stem (ES) cells. This assumption, however, remains
to be substantiated. In mammalian embryonic development,
chromosomal DNA undergoes two different physiological
reprogramming events: a first round following soon after
fertilization, and a second in primordial germ cells (Reik,
2007). Under physiological conditions, only germline-derived
chromosomes are subject to these reprogramming processes
(Fig. 1). Technologies that enable artificial reprogramming,
such as somatic cell nuclear transfer (SCNT), ES cell-somatic
cell fusion, and the induction of pluripotency in somatic cells,
are thought to mimic the physiological reprogramming thatFigure 1 Physiological and artificial reprogramming. In physiologic
for reprogramming. Somatic cells receive epigenetic modification dur
chromosomal DNA of somatic cells and these epigenetic modificatio
Weismann Barrier. Environmental epigenetic modifications on chromtakes places after fertilization, as such methods were
developed to establish a post-fertilization environment for
somatic chromosomes (Fig. 1) (Gurdon and Melton, 2008).
Although SCNT has shown that the genome state can be
reprogrammed to an early embryonic (zygotic) pattern, the
use of somatic cell nuclei from adult animals is inefficient, and
fewer than 6% of cloned mice embryos develop into births
(Rideout et al., 2001; Kishigami and Wakayama, 2009). The
process is also error-prone, and cloned mammals of different
species exhibit a variety of abnormal phenotypes, including
placental hyperplasia, large fetus syndrome, immune dis-
orders, and shortened life span (Tanaka et al., 2001;
Tamashiro et al., 2002; Ogonuki et al., 2002). Tissue-specific
gene expression profiles in cloned mice are also extremely
different from those generated by natural reproduction
(Kohda et al., 2005). Interestingly, most of the abnormal
phenotypes in clonedmice disappear after a single generation,
suggesting epigenetic alterations as a possible cause of the
abnormalities in gene expression profile and phenotype
(Tamashiro et al., 2002). Lending credence to this notion is
evidence that the epigenetic memory of active and repressed
transcription in nuclear-donor somatic cells can be inherited
through SCNT, in both mouse and Xenopus laevis (Ng and
Gurdon, 2005; Boiani et al., 2002; Bortvin et al., 2003).
Human iPSC colonies expressing Nanog and/or ALP
(alkaline phosphatase) following the forced expression of
Oct3/4, Sox-2, c-Myc and Klf4 show significant heterogeneity
characterized by a number of hallmark features (Fig. 2)
(Masaki et al., 2008). Such heterogeneity indicates the
different degrees of reprogramming in Nanog-and ALP-
positive colonies. Partially reprogrammed cells have also
been observed in human iPSCs induced by the forcedal conditions, chromosomal DNA of germ cells are the sole source
ing developmental and postnatal life. In physiological conditions,
ns are not inherited by the next generation, which is called the
osomes in germline cells and somatic cells must be different.
Figure 2 Heterogeneity of ALP-positive colonies induced by Oct3/4, Sox2, c-Myc and Klf4 genes from human dermis-derived cells.
(A) Heterogeneity of ALP-positive colonies was identified by analyzing the gene expression profile of eight marker genes. Although
Nanog gene expression was observed in 161 of 163 ALP-positive colonies, only four colonies expressed eight human ES cell marker
genes. The gene expression profile of the remaining 159 colonies was significantly heterogeneous; however, it had a characteristic
hierarchical feature. (B) The eight genes are aligned in the order of tendency to be expressed in ALP-positive colonies, NanogN
TDGF1N Dnmt3bN Zfp42N FoxD3N GDF3N CYP26A1N TERT. Eight genes were not randomly expressed by their tendency but showed a
hierarchical feature that expresses lower-tendency genes in colonies where higher-tendency genes are expressed. (C) Relation
between the transcriptional factor binding sites and the tendency of marker gene expression. Data was obtained from reference
(Masaki et al., 2008).
159Reprogramming-recalcitrant genesexpression of a different set of genes (Yu et al., 2007).
Recently, Chin et al. identified and described several
important features of a number of differentially expressed
genes in human ESCs and iPSCs (Chin et al., 2009). I will refer
to these as “reprogramming-recalcitrant” genes, as they
resist the induction of a transcriptional state identical to
that seen in embryonic stem cells. The underlying causes can
be categorized broadly as 1) insufficient induction of human
ES cell-specific genes; 2) insufficient suppression of somatic
cell-specific genes; and 3) induction of human iPSC-specific
genes. Of these, 1 and 2 correspond roughly to the causes of
recalcitrance to reprogramming by SCNT (Ng and Gurdon,
2005). It is important to recognize that genes that are not
expressed in pluripotent cells cannot be detected by gene
expression profiling in self-renewing human iPSCs, meaning
that there may be more reprogramming-recalcitrant genes in
human iPSCs than have been reported to date. The
measurement of genome-wide epigenetic marks is one
means of addressing this limitation. It was recently reportedthat, in human iPSCs, the DNA methylation landscapes of
chromosomes 12 and 20 are different from those of the same
chromosomes in human ES cells (Deng et al., 2009). This
raises the question of whether the incomplete resetting of
the nuclear state is a hallmark of artificial or post-
fertilization reprogramming or, in other words, whether it
is possible to achieve complete reprogramming by mimicking
post-fertilization reprogramming. The mechanistic basis and
functional roles of reprogramming-recalcitrant genes in the
resetting of somatic nuclei is also of great interest for further
study.Environmental epigenetic effects
Epigenetics refers to heritable modifications in gene function
without alteration of DNA sequences (Goldberg et al., 2007).
Chemical modifications to DNA and chromatin proteins are
the underlying drivers of epigenetic modifications. Although
160 K. Sakuradahuman DNA methylation occurs exclusively at cytosine
residues in CpG dinucleotides in differentiated cells, non-
CpG methylation, which is primarily observed at CpA
nucleotides, has recently been detected in stem cells (Lister
et al., 2009). Chromatin itself is composed of DNA and histone
proteins, which are subject to more than 100 different types
of modification, including methylation, acetylation, phos-
phorylation, and ubiquitination (Goldberg et al., 2007). The
term “epigenetics”was coined byWaddington to describe the
mechanisms necessary for the unfolding of genetic informa-
tion in ontogenic development (Waddington, 1942). Riggs
(Riggs, 1975) and Holiday and Pugh (Holliday and Pugh, 1975)
proposed that the programmed methylation and demethyla-
tion of DNA might be the molecular mechanism behind
Waddington's hypothesis, and it has since been shown that X-
chromosome-inactivation, genome imprinting, and lineage-
specific gene silencing all rely on DNA methylation.
Epigenetics do not function solely in the establishment
and maintenance of tissue-and cell-type-specific gene
expression. In addition to tissue-specific DNA methylation
regions (T-DMRs), alternative DNA methylation regions (A-
DMRs) have been identified by analyses of the DNA
methylation profiles of human chromosomes 6, 20, and 22
(Eckhardt et al., 2006). In this study, DNA methylation of T-
DMRs was found to occur preferentially in evolutionarily
conserved non-protein coding regions (ECRs) several kbp
distant from core promoters, while A-DMRs, which exhibit
cell mosaicism, were observed within the promoter. DNA
methylation profiles of A-DMRs vary between different
tissues in the same donor, as well as in the same tissues or
organs in different individuals, indicating that such regions
are acquired throughout life and depend on the specific
environmental stimuli at the cellular level.
Monozygotic (MZ) twins are highly similar in appearance,
especially at birth, yet they are frequently divergent for
several important phenotypes, including the onset of
common diseases (Wong et al., 2005). The concordance
of susceptibility to age-dependent diseases in MZ twins can
be quite low: 15% for breast cancer, 25%-30% for multiple
sclerosis, 25%-45% for diabetes, 50% for schizophrenia, and
40-70% for Alzheimer's disease (Wong et al., 2005; Petronis,
2006). Phenotypic divergence increases with age, and
greater differences are seen between MZ twins raised
and living in separate environments. Several different
mechanisms contribute to these changes, one of which is
epigenetic differences. To address this issue, Fraga et al.
analyzed global and locus-specific DNA methylation and
histone acetylation of a large cohort of MZ twins and
showed that, although such twins are epigenetically
indistinguishable in the early years of life, older MZ twins
exhibit remarkable differences in the overall content and
distribution of 5-methylcytosine and histone acetylation
(Fraga et al., 2005).
Findings from human epidemiological and animal studies
indicate that environmental stimuli can induce permanent
changes in phenotype, including metabolism and suscepti-
bility to chronic disease, at critical periods during pre-and
postnatal development, (Jirtle and Skinner, 2007). It has
also been suggested that epigenetic mechanisms are likely
involved in the developmental origins of health and disease
(Waterland and Michels, 2007). Although this remains the
subject of active discussion, environmental epigeneticsmay reflect an adaptive response to a given prenatal
environment that serves to optimize the postnatal pheno-
type to meeting the challenges of that environment
(Gluckman and Hanson, 2004; Huxley et al., 2007). It has
been suggested, for example, mismatches between pre-and
postnatal environments may be linked to increases in the
risk of developing chronic diseases, including type II
diabetes, hypertension, and coronary heart disease (Gluck-
man and Hanson, 2004).
Although the molecular mechanisms by which environ-
mental stimuli alter gene expression to achieve phenotypic
diversity are largely unknown, changes in the concentration
of fetal hormones, such as glucocorticoids, may serve as
molecular cues. Glucocorticoids have been shown to alter
DNA methylation at the promoter of the glucocorticoid
receptor. Maternal behaviors in rat, for example, have been
shown to influence the epigenetic modification of the
promoter of the glucocorticoid receptor in neurons (Weaver
et al., 2004). In this study, the glucocorticoid receptor gene
promoter was epigenetically repressed in the hippocampus
of the offspring of low “licking and arched-back nursing”
mothers (Weaver et al., 2004). Another study has shown that
chronic social defeat stress induces methylation of lysine 27
(K27) of the histone H3 adjacent to the promoter region of
the brain-derived neurotrophic factor (BDNF) gene in
hippocampal neurons (Tsankova et al., 2006).
Developing organisms are also extremely sensitive to
chemical perturbation. Environmental compounds, drug
administration, and physiological stresses in embryogenesis
and the early postnatal period have been demonstrated to
influence the pathogenesis and course of adult onset
diseases (Hellwig et al., 2000). For example, endocrine
disruptors, such as vinclozolin and diethylstilbestrol, induce
reproductive and endocrine defects (Hellwig et al., 2000;
Klip et al., 2002). The frequency and reproducibility of such
abnormal phenotypes strongly suggest that epigenetic
modifications, not genetic mutations, are causative, and
indeed, aberrant DNA methylation of several genes has been
found in tissues and cells exposed to diethylstilbestrol
(Bromer et al., 2009). Cultured cells exposed to benzopyrene
additionally exhibited genome-wide alterations in histone H3
lys9 acetylation (Sadikovic et al., 2008).
Clearly, exposure to different environmental factors,
including nutritional, endocrine, and chemical perturbation
throughout life, influences the epigenetic landscape of
each individual. These epigenetic modifications can be
distinguished with developmental epigenetics and is called
environmental epigenetics.
Stem cells as generators and transmitters of
environmental epigenetic modifications
Environmental epigenetic modifications introduced into
terminally differentiated cells of post-mitotic tissues or
organs, such as neurons or cardiomyocytes, can play
indispensable functional roles (Weaver et al., 2004;
Tsankova et al., 2006; Zhang et al., 2002), but are not
transmitted. In contrast, epigenetic modifications in
somatic stem cells in mitotically active tissues can be
passed on to progeny cells, meaning that somatic stem cell
epigenetic modifications that occur at early developmental
161Reprogramming-recalcitrant genesstages may be transmitted large, tissue-specific cellular
populations or lineages over the life of the organism.
Importantly, proliferating cells, including stem and pro-
genitor cells, have a higher tendency to undergo epigenetic
modification (Meissner et al., 2008). During DNA replica-
tion, the disruption, transfer, and de novo assembly of
nucleosomes are coordinated to reproduce the epigenetic
landscape (Groth et al., 2007). Because these genome-wide
rearrangements of chromosome structure occur during DNA
replication, the mitotic S phase may provide a unique
opportunity for epigenetic modification to occur. As an
example, culture-induced instability of DNA methylation in
ES and somatic cells has been observed in high-CpG
promoters (Meissner et al., 2008; Allegrucci et al., 2007).
The DNA in somatic cells in mitotically active tissues also
tends to be more highly methylated, which has been
suggested as a possible cause of replicative aging (Chu et
al., 2007). High-turnover tissues also show higher rates of
cancer development (Rando, 2006; Sakurada et al., 2008).
The cell mosaicism of A-DMRs described above supports the
notion that stem cells can serve as generators and
transmitters of environmental epigenetic modifications.
The nature of reprogramming-recalcitrant
genes
Given the evident importance of environmental epigenetic
changes in ontogeny, physiology, and pathogenesis, it
seems clear that the extent of reprogramming should be
assessed with reference not only to developmental
epigenetics, but environmental epigenetics as well. A
large body of evidence on the inheritance of environmen-
tal epigenetics following physiological reprogramming has
been compiled, and indicates that transgenerational
epigenetic effects define phenotypes present in successive
generations that are not genetically determined (Yongson
and Whitelaw, 2008). Specifically, environmental epige-
netic modifications in germline cells may play a major role
in transgenerational phenotypes. A number of examples of
adaptive and non-adaptive transgenerational effects have
been found in mammals, including humans (Yongson and
Whitelaw, 2008). Not all transgenerational epigenetic
phenotypes can be explained by the inheritance of
epigenetic marks that avoid zygotic and germline repro-
gramming. It has been shown, however, that a patient
suffering hereditary nonpolyposis colorectal cancer
(HNPCC) had abnormal DNA methylation of the DNA
mismatch repair genes, MLH1, in all three germ layers
inherited from parental germ cells that escaped zygotic
reprogramming (Hitchins et al., 2007). The incomplete
reprogramming observed in SCNT and iPSCs could similarly
correspond to zygotic reprogramming.
As suggested by the heterogeneity of A-DMRs (Eckhardt et
al., 2006), environmental epigenetics may mirror common
differences between germline and somatic cells as deter-
mined by differences in niche microenvironments. If so, this
raises the possibility that the artificial reprogramming of
somatic cells may generate disease phenotypes, which are
usually not caused by the reprogramming recalcitrant genes
inherited through physiological reprogramming of the germ-
line cell nucleus.Challenges in the application of human iPSCs
Much has been written about potential applications for
human iPSC technology in the study of disease etiology and
patient-specific cell replacement therapy. The existence of
reprogramming-recalcitrant genes, however, may signify
important constraints on such applications. We have seen
how epigenetic modifications can influence disease pheno-
types by affecting gene expression levels, irrespective of
DNA sequence. The causes of the phenotype differences
observed in somatic cells differentiated from patient-
specific iPSCs may be complex, as these may be the result
of variations in DNA sequence or the activity of iPSC-specific
reprogramming-recalcitrant genes. Environmental epigenet-
ic marks inherited from somatic cell sources also exhibit cell
mosaicism. This suggests that the only way to reconstitute
the disease-specific phenotypic features resulting from
inherited environmental epigenetic modifications in pa-
tient-specific human iPSCs may be to induce pluripotency
in somatic cells from the affected tissue.
Neural stem cells are currently being considered as
potential therapies for neurological disorders. It was
recently reported that a boy suffering ataxia telangiectasia
who had received multiple injections of fetal neural cells
into the brain developed a multifocal brain tumor derived
from the donor cells (Amariglio et al., 2009). Importantly,
the fetal neural cells were cultured before transplantation
(Amariglio et al., 2009). Culture-induced DNA methylation
instability has been observed in the epigenome of human ES
cells as well as in that of somatic cells (Meissner et al., 2008;
Allegrucci et al., 2007). It is conceivable, therefore, in this
unfortunate case that the cancer-prone epigenetic pheno-
type was acquired during culture. The possibility that de
novo epigenetic modification during the iPSC-generating
process may also induce epigenetic phenotypic changes
cannot be ruled out.
The role of reprogramming-recalcitrant genes in human
iPSCs needs to be considered seriously. Epigenetics is a
latent change in gene function, which cannot be detected
comprehensively by gene expression profile. At present,
there is no technology able to accurately measure genome-
wide epigenetic modifications at the single-cell level, and
thus it remains impossible to prospectively identify
potentially small populations of cancer-prone cells in a
cell therapy product. The use of sample-based statistics
can help to address this epigenetic heterogeneity, and
should be applied in the evaluation of cells intended for
use in the study of disease etiology or cell-based therapy.
Ideally, a larger number of samples than is typically used in
clinical studies should be used to improve accuracy and
statistical power.
Optimization of human iPSC generation
The quality of human iPSCs should be evaluated in respect to
their retention of environmental as well as developmental
epigenetic marks. The definition of human iPSCs remains
ambiguous, even in terms of true pluripotency. For example,
most publications to date have examined the expression only
of Nanog or ALP as a surrogate in determining increases in
the efficiency of iPSC generation (Hong et al., 2009; Yoshida
162 K. Sakuradaet al., 2009). However, the presence of partially repro-
grammed developmental genes in Nanog-and/or ALP-posi-
tive human colonies indicates that the increase in the
efficiency of pluripotent cell generation through the use of
newly developed reprogramming methods cannot be con-
firmed without evaluating the expression of multiple
pluripotency genes, including Nanog, TDGF1, Dnmt3b,
Zfp42, FoxD3, GDF3, Cyp26A1 and TERT, in all colonies
generated in the primary induction culture (Masaki et al.,
2008) (Fig. 3A). Absent such confirmatory evidence,
increases in the number of Nanog-and/or ALP-positive
colonies may only indicate an increase in the number of
partially reprogrammed cells. To my knowledge, no evalu-
ation of environmental epigenetic modifications, such as
those caused by disease states in somatic cells of origin or
cell culture, have been conducted on human iPSCs. It should
be emphasized that functional analyses using the present
criteria for pluripotency are insufficient to determine the
quality of human iPSCs in terms of their environmental
epigenetics. The differentiative potential of iPSCs does not
necessarily reflect the full set of disease-associated epige-
netic modifications that may be inherited from their somatic
cells of origin.
Without clear evidence of bona fide complete reprogram-
ming, in which all unnecessary epigenetic marks in somatic
cells is erased, it is essential to optimize the process ofFigure 3 Evaluation and optimization of degree of epigenetic repro
colonies may reflect the generation of partially reprogrammed ce
contribute to the degree of developmental epigenetic reprogrammin
culture-induced epigenetics will contribute to the degree of environhuman iPSC generation by identifying epigenetically ideal
somatic cell sources (Fig. 3B). Although the generation of
pluripotent stem cells from lymphocytes, monocytes/macro-
phages, and albumin-or insulin-producing cells has been
proposed, based on the assumption that all somatic cells,
including terminally differentiated cells, have the ability to
be reprogrammed to pluripotency, this may be a leap too far
(Yamanaka, 2009). Studies of DNA methylation profiles in
sperm and lymphocytes revealed relatively smaller differ-
ences, consistent with the similarities between their gene
expression profiles (Eckhardt et al., 2006; Zeng et al., 2004).
Monocytes and macrophages express multiple lineage genes
by differentiation or by cell fusion (Zhao et al., 2003;
Camargo et al., 2003). These characteristics are not
observed in other terminally-differentiated cells. Addition-
ally, the expression of tissue-specific genes, such as those
encoding albumin or insulin, cannot serve as the basis for the
reprogramming of terminally-differentiated cells, since it
has been shown that these genes can also be expressed in
somatic stem cells during wound healing and cell culture
(Rountree et al., 2007). It has been shown that Bmi-1
modification is essential in self-renewing hematopoietic and
neural stem cells in an Ink4a-dependent manner (Park et al.,
2003; Molofsky et al., 2003). Thus, the increase in the
efficiency of colony formation by inhibition of the Ink4/arf
pathway means that somatic stem cells are favorable sourcesgramming. Increase in the number of Nanog and/or ALP-positive
lls. The degree of differentiation in somatic cell sources will
g. On the other hand, the epigenetic background of a donor, and
mental epigenetic reprogramming.
163Reprogramming-recalcitrant genesfor iPSC reprogramming (Li et al., 2009). And indeed, the
reprogramming of somatic stem cells has been shown to be
more efficient than that of skin-derived cells (Silva et al.,
2008; Eminli et al., 2009).
Although human iPSCs have been established from
elderly donors, their quality was not analyzed with respect
to environmental epigenetics (Dimos et al., 2008). Global
hypomethylation and local hypermethylation are commonly
observed in cancer and senescent cells (Suzuki et al.,
2006), and age-dependent hypermethylation is observed at
A-DMRs, indicating that environmental epigenetics may
increase with cell senescence. These observations indicate
that young donors may be preferable to elderly donors as
sources for somatic cells used in the generation of human
iPSCs. Mitotically inactive tissue is also known to undergo
less DNA methylation at A-DMRs (Chu et al., 2007). Given
with these observations regarding DNA methylation and the
instabilities associated with proliferation, it stands to
reason that minimally passaged somatic stem cells derived
from low-turnover tissues may represent optimal starting
cell sources for use in the generation of human iPSCs.
Conclusions
The available evidence indicates that reprogramming is
incomplete in human iPSCs, and that reprogramming-
recalcitrant genes may influence both human iPSC function
and the phenotypes of their differentiated progeny. It is
thus necessary to determine the epigenetic state of
“wildtype” pluripotent stem cells in regard to both their
developmental and environmental epigenetics. Under-
standing the mechanisms of environmental epigenetics
and transgenerational epigenetic inheritance will offer
new methods for manipulating epigenetic marks. The use
of chemical compounds that modify the function of
epigenetic enzymes, such as histone deacetylase (HDAC),
histone methylase (HMT), and DNA methyltransferase
(Dnmt), may help to improve reprogramming efficiencies,
and in fact, it has been shown that HDAC and Dnmt1
inhibitors do just that (Huangfu et al., 2008). However,
these compounds affect genome stability by targeting
various cellular genomic surveillance mechanisms (Eot-
Houllier et al., 2009). Evidence that epigenetics processes
are regulated by RNA signaling is also beginning to
accumulate (Mattick et al., 2009). Compared to epigenetic
enzymes and chromatin-modifying complexes (Polycomb-
group and Trithorax-group), RNA-directed regulation of
chromosome modification may offer the advantage of a
high degree of sequence-and locus-specificity. Non-protein
coding RNAs (ncRNAs) play a major role in this process. A
better understanding of the mechanisms of ncRNA-mediat-
ed epigenetic modification may provide us with new tools
for controlling epigenetic modifications associated with
disease susceptibility and pathogenesis.
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